Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 4/2011

01-04-2011 | Letter to the Editor

Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations

Authors: Sebastian Scholl, Baerbel Spies-Weisshart, Anne Klink, Lars-Olof Muegge, Hans-Joerg Fricke, Andreas Hochhaus

Published in: Annals of Hematology | Issue 4/2011

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Yokota S, Kiyoi H, Nakao M, Minami S, Kuriyama K, Takeshita A et al (1997) Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies: a study on a large series of patients and cell lines. Leukemia 11:1605–1609PubMedCrossRef
2.
Kottaridis PD, Gale RE, Frew ME, Harrison G, Wheatley K, Groves MJ et al (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98:1752–1759PubMedCrossRef
3.
Thiede C, Steudel C, Mohr B, Schaich M, Schaekel U, Platzbecker U et al (2002) Analysis of Flt3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326–4335PubMedCrossRef
4.
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390PubMedCrossRef
5.
Zhang W, Konopleva M, Shi YX, Shih YX, McQueen T, Harris D et al (2008) Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 100:184–198PubMedCrossRef
6.
von Bubnoff N, Engh RA, Aberg E, Saenger J, Peschel C, Duyster J (2009) FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res 69:3032–3041CrossRef
7.
Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A (2009) Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 113:6567–6571PubMedCrossRef
8.
Safaian NN, Czibere A, Bruns I, Fenk R, Reinecke P, Dienst A et al (2009) Sorafenib (Nexavar [registered]) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD acute myeloid leukemia. Leuk Res 33:348–350PubMedCrossRef
9.
Mori S, Cortes J, Kantarjian H, Zhang W, Andreef M, Ravandi F (2008) Potential role of sorafenib in the treatment of acute myeloid leukemia. Leuk Lymphoma 49:2246–2255PubMedCrossRef
10.
Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers J et al (2008) Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 112:2024–2027PubMedCrossRef
11.
White DL, Saunders VA, Dang P, Engler J, Zennettino AC, Cambareri AC et al (2006) OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108:697–704PubMedCrossRef
12.
Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE (2008) Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 83:258–264PubMedCrossRef
13.
La Rosée P, Hochhaus A (2010) Molecular pathogenesis of tyrosine kinase resistance in chronic myeloid leukemia. Curr Opin Hematol 17:91–96PubMedCrossRef
Metadata
Title
Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations
Authors
Sebastian Scholl
Baerbel Spies-Weisshart
Anne Klink
Lars-Olof Muegge
Hans-Joerg Fricke
Andreas Hochhaus
Publication date
01-04-2011
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 4/2011
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-010-1027-9

Other articles of this Issue 4/2011

Annals of Hematology 4/2011 Go to the issue

Original Article

CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11)

Original Article

Circulating procoagulant microparticles in cancer patients

Letter to the Editor

Plasmodium vivax malaria-associated hemophagocytic lymphohistiocytosis in a young man with pancytopenia and fever

Original Article

Outpatient treatment with intravenous antimicrobial therapy and oral levofloxacin in patients with febrile neutropenia and hematological malignancies

Letter to the Editor

Hemolysis in Wilson’s disease

Original Article

Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits